Australia's most trusted
source of pharma news
Posted 19 May 2022 AM
Unable to keep up with the off-label demand for Ozempic being used as a 'miracle' weight loss drug, Novo Nordisk has demanded the drug to be prioritised for its approved use.
In a joint statement developed with the TGA and relevant stakeholders, Novo said, "the shortage is significantly affecting people using Ozempic for its approved used for type 2 diabetes".
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.